Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

GRANISETRON HCL

All products: Limited Use (codes 326, 454, 91, 92, 93)

Other products in the same Health Canada class (A04A, A04AA) — coverage varies; not interchangeable

  • Netupitant + palonosetron (Akynzeo): limited Use 561, 562
  • Ondansetron (Zofran ODT (Tablet)): limited Use 215, 216, 217, 218, 454, 696, Not a benefit
  • Ondansetron (Zofran): not a benefit
  • Nabilone (Cesamet): general benefit, Not a benefit
  • Aprepitant (Emend Tri-Pack): limited Use 452, 453

Jamp Granisetron · DIN 02472686 · 1mg · tablet

Limited Use — Reason for Use code 91, 92, 93, 326, 454 requiredDormant since 2024-07-31 · checked 2026-09-19 · What does dormant mean?
StatusLimited Use — Reason for Use code 91, 92, 93, 326, 454 required
Write on scriptLU code 91, 92, 93, 326, 454 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 91, 92, 93, 326, 454
Reason for Use code 91 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 92 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 93 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti- emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 326 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of GRANISETRON HCL more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Jamp Granisetron · DIN 02472686 Manufacturer: Jamp Pharma Corporation; listing date 2020-12-18 Health Canada: Dormant since 2024-07-31 · brand JAMP GRANISETRON · ATC A04AA02 GRANISETRON · form Tablet · route Oral · ingredients GRANISETRON (GRANISETRON HYDROCHLORIDE) 1 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Granisetron: Formulary list price $4.5000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $4.5000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96198 · Verify on the e-Formulary ↗ (DIN 02472686)

Source record
DIN 02472686: Jamp Granisetron Raw flags: sec12=Y, sec3=Y Item: 562200024; group id 666; item number 1654; lccId 00101; manufacturer id JPC Source form: Tab; strength: 1mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $4.5000; ministry $4.5000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02472686 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96198
Interchangeable products
Apo-Granisetron · DIN 02308894 · $4.5000 Kytril · DIN 02185881 · not recorded Nat-Granisetron · DIN 02452359 · $4.5000
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since 2024-07-31 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL Some products covered without a code (check the product listing): NABILONE 56:22 Antiemetics and Antinauseants

NETUPITANT & PALONOSETRON HYDROCHLORIDE

· 1 products · Limited Use, codes 561, 562 · strengths: 300mg & 0.5mg · Cap

ONDANSETRON HYDROCHLORIDE

· 54 products · Listed, not a benefit (5), Limited Use, codes 215, 216, 217, 218, 454, 696 (49) · strengths: 4mg, 8mg, 4mg/5mL · O/L, Tab

ONDANSETRON HCL DIHYDRATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg/mL · Inj Sol-2mL Pk, Inj Sol-4mL Pk

NABILONE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (6) · strengths: 0.25mg, 0.5mg, 1mg · Cap

APREPITANT

· 1 products · Limited Use, codes 452, 453 · strengths: 125mg & 80mg · Cap

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

DIMENHYDRINATE

· 2 products · Limited Use, codes 481 · strengths: 50mg/mL · Inj Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:22
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: download failed: TimeoutError
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)